What Caris Life Sciences's Quarter ended Sep 30, 2026 10-Q says: 4 signals
Caris Life Sciences filed its latest 10-Q with the SEC on Nov 4, 2026. It discusses AI investment, customer concentration and internal control weakness.
Public (CAI)Biotechnology Research1,001 to 5,000 employeescarislifesciences.comLinkedIn
Get Caris Life Sciences' live signals in Claude or ChatGPT, or by API
What changed at Caris Life Sciences this week? Use Autobound signals for carislifesciences.com.- Filed
- Nov 4, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 11
Source: Autobound Signal API · 74 signals tracked for Caris Life Sciences · updated
10-Q · latest 10
What Caris Life Sciences's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 4 signals
Commercial launch of Caris Detect, Caris ChromoSeq, and Caris MI Clarity in Q2 2026
Caris Life Sciences expanded its molecular and digital diagnostic offerings in the second quarter of 2026 with the launches of Caris Detect, Caris ChromoSeq, and Caris MI Clarity.
Whole Genome SequencingWhole Transcriptome Sequencingartificial intelligencecomputational pathology
Management concluded disclosure controls and procedures were not effective as of September 30, 2026, due to a lack of sufficient qualified accounting resources for complex calculations and technical accounting.
Caris Launched AI/ML-Based Prognostic Solution Caris MI Clarity in Q2 2026
During the second quarter of 2026, Caris launched Caris MI Clarity, its first commercially available digital prognostic solution applying computational pathology and machine learning to digitized whole-slide images and clinical inputs.
AIMLmachine learningcomputational pathology
Medicare accounted for 36.9% of molecular profiling services revenue in Q3 2026
Revenue from clinical cases covered by Medicare represented approximately 36.9% of molecular profiling services revenue for the three months ended September 30, 2026.
36.9%
share of molecular profiling services revenue from Medicare patients
- SEC EDGAR
10-Q · Quarter ended Jun 30, 2026
Filed · 4 signals
Commercial Launch of Caris Detect, Caris ChromoSeq, and Caris MI Clarity in Q2 2026
During Q2 2026, Caris expanded its platforms by commercially launching Caris Detect, Caris ChromoSeq, and Caris MI Clarity.
Whole Genome SequencingWhole Transcriptome Sequencingartificial intelligencemachine learning
Material Weakness in Internal Control Reported Due to Insufficient Qualified Accounting Resources
Management concluded disclosure controls were not effective as of June 30, 2026, due to an ongoing material weakness from a lack of sufficient qualified accounting resources for complex calculations.
Medicare Patients Represented 38.9% of Molecular Profiling Services Revenue in Q2 2026
Revenue from clinical cases covered by Medicare accounted for approximately 38.9% of Caris Life Sciences' molecular profiling revenue for the three months ended June 30, 2026, compared to 49.7% in Q2 2025.
38.9%
share of molecular profiling services revenue from Medicare patients
- SEC EDGAR
10-Q · Quarter ended Mar 31, 2026
Filed · 3 signals
Material weakness in internal control stems from lack of qualified accounting resources
Caris Life Sciences reported disclosure controls were ineffective as of March 31, 2026, due to an ongoing material weakness from a lack of sufficient qualified accounting resources to evaluate complex transactions under GAAP and SEC rules.
Disclosure controls ineffective as of March 31, 2026 due to accounting resource material weakness
Caris reported ineffective disclosure controls and procedures as of March 31, 2026 due to an ongoing material weakness in internal control over financial reporting regarding insufficient qualified accounting resources.
Medicare accounted for 41.2% of molecular profiling services revenue in Q1 2026
Revenue from clinical cases for patients covered by Medicare represented approximately 41.2% of molecular profiling services revenue for the three months ended March 31, 2026, down from 54.3% in the prior year period.
41.2%
share of molecular profiling services revenue from Medicare
Showing 10 of 11 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Caris Life Sciences earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Revenue up 27% to $275.4M, clinical volume grows 21%Caris achieved record third-quarter revenue of $275.4 million, up 27% year-over-year, driven by 61,500 clinical cases. Molecular profiling revenue was $262.7 million with a blended ASP of $4,272. Adjusted EBITDA hit $44.4 million with GAAP net income of $15.3 million. | |
| Deploying upgraded Caris Assure on Illumina NovaSeq X platformCaris upgraded its Caris Assure liquid biopsy assay onto Illumina's NovaSeq X sequencing platform to significantly boost depth and reach. Management also noted they remain technology-agnostic and are evaluating competing sequencing platforms to lower future cost of goods sold. | |
| Expanding ACHIEVE clinical program to four studies with 63,000 patientsCaris is expanding its ACHIEVE clinical validation program to four studies encompassing 63,000 patients to demonstrate early-stage cancer sensitivity for Caris Detect. ACHIEVE 2 has enrolled 20,000 of its 25,000 target with an interim readout expected in Q1 2027, while ACHIEVE 3 (10,000 patients) and ACHIEVE 4 (25,000 patients) are currently in planning. | |
| Partnering with Everlywell and concierge networks for Detect distributionCaris is pursuing direct-to-consumer and cash-pay channel distribution for Caris Detect through digital health platforms including Everlywell and concierge medicine networks. Management is avoiding traditional primary care physician channels while ramping consumer marketing campaigns. | |
| Sales territories expanded from 82 to 146 following realignmentCaris completed a structural realignment of its commercial organization, scaling from 82 to 146 sales territories. The reorganization continues to drive accelerated clinical case volume across both tissue and liquid biopsy testing. | |
| Competing against methylation-based MCED tests and stool-based diagnosticsCaris criticized competing early detection assays that rely purely on methylation technology, stating methylation fails to detect cancers in early Stage 1 and 2. The company is actively positioning its whole-genome blood test against methylation tests and single-cancer stool-based screenings. |
Signal API · MCP
Track Caris Life Sciences with the Signal API
One POST /v1/companies/enrich call with carislifesciences.com returns Caris Life Sciences 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"carislifesciences.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about Caris Life Sciences 10-Q
When did Caris Life Sciences file its latest 10-Q?
What did Caris Life Sciences disclose in its latest 10-Q?
What did Caris Life Sciences say on its recent earnings calls?
Where can I read Caris Life Sciences's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .